

## Drug Monograph

Drug/Drug **Lithium Citrate (lithium) syrup / Mood Stabilizer**

Class:

Prepared for: MO HealthNet

Prepared by: Xerox Heritage LLC

**New Criteria**

**Revision of Existing Criteria**

### Executive Summary

**Purpose:** The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

**Dosage Forms:** Lithium citrate syrup is supplied as 8 mEq/5mL which is equivalent to the amount of lithium in 300mg of lithium carbonate.

**Manufacturer:** Morton Grove Pharmaceuticals, Inc.  
Morton Grove, IL 60053

**Indications:** Lithium citrate is indicated in the treatment of manic episodes of Bipolar Disorder. Lithium is also indicated as a maintenance treatment for individuals with a diagnosis of Bipolar Disorder to reduce the frequency of manic episodes.

**Costs:** \$ 0.16 per mL of lithium citrate. Wholesale Acquisition Cost

**Summary of Findings:** The Division recommends adding this drug to the current psychotropic polypharmacy clinical edit.

**Status Recommendation:**  Prior Authorization (PA) Required  Open Access  
 Clinical Edit  PDL

**Type of PA Criteria:**  Increased Risk of ADE  Preferred Agent  
 Appropriate Indications  No Prior Authorization Required

Prepared By: Katie Wilbers, PharmD

Date: January 14, 2013